Filtered By:
Management: Food and Drug Administration (FDA)
Countries: Turkey Health
This page shows you your search results in order of date.
Order by Relevance | Date
Total 141 results found since Jan 2013.
Management of Primary Biliary Cholangitis: Current Treatment and Future Perspectives
Turk J Gastroenterol. 2023 Feb;34(2):89-100. doi: 10.5152/tjg.2023.22239.ABSTRACTPrimary biliary cholangitis is an autoimmune cholestatic liver disease characterized by progressive destruction of bile ducts, which can ultimately progress to chronic liver disease and cirrhosis. Ursodeoxycholic acid and obeticholic acid are the only 2 Food and Drug Administration (FDA)-approved medications for primary biliary cholangitis. Unfortunately, up to 40% of patients with primary biliary cholangitis have an incomplete response to ursodeoxycholic acid, warranting an essential need for additional therapeutics. Peroxisome proliferator-a...
Source: The Turkish Journal of Gastroenterology - February 27, 2023 Category: Gastroenterology Authors: Romelia Barba Bernal Bryan Ferrigno Esli Medina Morales Cristina M Castro Daniela Goyes Hirsh Trivedi Vilas R Patwardhan Alan Bonder Source Type: research
Isotretinoin Induced Psychotic Mania: A Case Report
Turk Psikiyatri Derg. 2021 Fall;32(3):214-218.ABSTRACTBiological, genetic and psychosocial factors may play a role in the aetiology of bipolar mood disorder (BPD). BPD episodes might be triggered by isotretinoin, a retinoid derivative of vitamin A with a role in cellular proliferation and differentiation. Due to its association with depression, suicidal ideation and suicide attempts, American Food and Drug Administration (FDA) issued a placement of a label warning for isotretionin. Personal or family history of psychiatric disorders was emphasized in the literature for the risk of mood episodes following isotretionin treat...
Source: Turkish Journal of Psychiatry - November 9, 2021 Category: Psychiatry Authors: Faruk Kurhan G ülsüm Zuhal Kamiş Source Type: research
